PortViewPortView
Vyome logo

Vyome (HIND) Stock Analysis

NASDAQHealthcareBiotechnology

$2.17+0.00%
1-year price historyRange $1.89 – $8.56
52-week range$2.17
$1.75$9.56

What Vyome does

Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.

Key metrics

Market cap
$15.23M
P/E (TTM)
-0.36
EPS (TTM)
$-5.99
Beta
1.49
Dividend yield
0.00%
Revenue / share
$0.02
50-day avg
$2.17
200-day avg
$2.73
52-week high
$9.56
52-week low
$1.75
CEO
Venkateswarlu Nelabhotla

ETFs linked to HIND

Broad-market and Healthcare sector ETFs an investor holding Vyome is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how HIND fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze HIND in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Vyome?
Vyome trades under the ticker HIND on NASDAQ.
Which exchange is HIND listed on?
HIND is listed on NASDAQ.
What sector does Vyome operate in?
Vyome is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze HIND in a portfolio?
PortView shows HIND's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.